Abstract: Mammalian bombesin-like peptides neuromedin B (NMB) and gastrin-releasing peptide (GRP) act by activating NMB receptors (NMBR, BB1) and GRP receptors (GRPR, BB2), respectively. These two bombesin receptors are members of the G-protein-coupled receptor (GPCR) superfamily. In the brain, NMBR and GRPR are highly expressed in the brain areas involved in memory processing and emotional responses, such as the hippocampus and the amygdaloid nuclei. An increasing number of pharmacological and genetic studies in rodents indicate that NMBRs and GRPRs in brain regions including the dorsal hippocampus, the nucleus tractus solitarius, the basolateral amygdala, and cortical areas, regulate memory formation and expression, particularly for memories related to emotionally arousing tasks. GRPR signaling interacts with multiple protein kinase pathways as well as with other neurotransmitter, hormone, and growth factor systems in influencing memory formation. Together with evidence from human studies, the findings from rodent experiments suggest that bombesin receptors may be therapeutic targets in brain disorders involving memory dysfunction and anxiety.
of neuropeptide signaling in rodents (for reviews, see Engelmann et al., 1996; Feany, 1996; de Wied, 1997; Fehm et al., 2000; Roesler and Schr ö der, 2011) . This review will focus on the role of BLPs in influencing the formation and expression of emotional memories.
Bombesin family of neuropeptides
Bombesin is an amidated, 14-amino acid peptide isolated from the skin of the European frog Bombina bombina in 1970. The bombesin group of amphibian peptides was characterized as having the carboxyl terminus of Gly-HisLeu-Met-NH 2 (Erspamer et al., 1970) . Bombesin was biologically active when administered in the mammalian central nervous system (CNS), as indicated by experiments showing that intracerebroventricular (i.c.v.) infusions of bombesin induced hypothermia and hyperglycemia in rats (Brown et al., 1977a,b) . Subsequently, two mammalian BLPs, gastrin-releasing peptide (GRP) and neuromedin B (NMB), were identified (McDonald et al., 1979; Minamino et al., 1983) . GRP, originally isolated from the porcine stomach, has 27 amino acids, which is synthesized as a 148-amino acid precursor (PreproGRP) and subsequently metabolized posttranslationally (Spindel et al., 1984 (Spindel et al., , 1990 LebacqVerheyden et al., 1988) . GRP and bombesin display similar biological activities and both peptides share the same seven carboxyl-terminal amino acids. NMB, the mammalian equivalent of the amphibian peptide ranatensin, is a decapeptide originally isolated from the porcine spinal cord ( Table 1 ; Minamino et al., 1983) . Another peptide originally named neuromedin C (Minamino et al., 1984) is in fact a decapeptide of GRP ).
Studies investigating the presence of bombesin-binding sites in the mammalian CNS showed that bombesin could bind with high affinity to rat brain membranes, with high specific binding sites in brain areas including the hippocampus (Moody et al., 1978) . The presence of endogenous BLPs in the rat brain was demonstrated by radioimmunoassay techniques, showing high concentrations in the nucleus tractus solitarius (NTS), the amygdala, and the hypothalamus (Moody and Pert, 1979; Moody et al., 1981) . GRP and NMB mRNAs have differential distribution patterns across rat brain areas (Chronwall et al., 1985; Wada et al., 1990) . NMB mRNA is most abundant in the olfactory bulb, the dentate gyrus, and the dorsal root ganglia, whereas GRP mRNA has the highest density in the forebrain areas and the hypothalamus (Wada et al., 1990; Battey and Wada, 1991 ; for reviews, see Moody and Merali, 2004; Roesler et al., 2006a; Jensen et al., 2008) .
Mammalian bombesin receptors
The development of selective antagonists allowed the identification of two different mammalian receptors mediating the effects of BLPs: one with higher affinity for NMB than GRP (NMB receptor, NMBR) and the other binding preferentially to GRP with lower affinity for NMB (GRP receptor, GRPR; Jensen and Gardner, 1981; Moody et al., 1988 Moody et al., , 1992 von Schrenck et al., 1989 von Schrenck et al., , 1990 Ladenheim et al., 1990 Ladenheim et al., , 1992 Wang et al., 1992) . The first bombesin receptor to be cloned, from murine Swiss 3T3 cells, was GRPR in 1990 (Spindel et al., 1990; . Subsequently, NMBR was cloned from a cDNA library made from the rat esophagus , and the structures of human NMBR and GRPR were described from a small-cell lung cancer cell line . In addition to NMBR and GRPR, a third mammalian bombesin receptor was cloned in 1992, originally from guinea pig uterus (Gorbulev et al., 1992) and later from human (Fathi et al., 1993) , mouse (Ohki-Hamazaki et al., 1997) , rat (Liu et al., 2002) , and sheep (Whitley et al., 1999) . This receptor, named BRS-3, shows low affinity for all known BLPs and to date is considered an orphan receptor . The current terminology adopted by several receptor classification guides uses the names BB1, BB2, and BB3 for NMBRs, GRPRs, and BRS-3 receptor, respectively. More recently, novel bombesin receptors with no mammalian equivalents have been identified in amphibians (BB4; Nagalla et al., 1995) and chickens (chBRS-3.5; Iwabuchi et al., 2003) . Figure 1 illustrates the mammalian bombesin receptors and their endogenous ligands in mammals described to date.
All bombesin receptors are members of the G-proteincoupled receptor (GPCR) superfamily and exhibit the characteristic seven-transmembrane domain structure of GPCRs. Below we will present a brief overview of the structure and signaling of the three mammalian bombesin receptors (for a comprehensive review on bombesin receptor classification, nomenclature, expression, signaling, Table 1 Structures of bombesin, GRP, and NMB. The amino acid sequence data are from as follows: bombesin: Anastasi et al., 1972; GRP: Sausville et al., 1986; Spindel et al., 1986; and NMB: Krane et al., 1988 ; for a review, see Jensen et al., 2008. and functions, see Jensen et al., 2008 ; see also Gonzalez et al., 2008 for an excellent review on bombesin receptor functions). Table 2 shows a summary of the molecular structures of NMBR, GRPR, and BRS-3 receptors.
NMBR (BB1)
The NMBR has 390 amino acids in humans, rats, and mice. The human NMBR shows 55% identity with human GRPR and 47% identity with human BRS-3 . The human NMBR gene ( NMBR ) is localized at chromosome 6p21-qter, the mouse gene ( Nmbr ) on chromosome 10 A2, and the rat Nmbr on 1p13 ( Table 2 ; Jensen et al., 2012) . In rats and mice, NMBR is expressed in gastrointestinal and urogenital tissues and is widely spread within the brain, particularly in the olfactory tract Ohki-Hamazaki et al., 1997) . The NMBR is coupled to the G q protein (G q ) and the phospholipase C (PLC)/protein kinase C (PKC) signaling pathway, and its activation leads also to stimulation of phospholipases A 2 and D and extracellular signal-regulated protein kinase (ERK)/mitogen-activated protein kinase (MAPK; Corjay et al., 1991; Wada et al., 1991; Moody et al., 1992 Moody et al., , 1995 Wang et al., 1992; Dobrzanski et al., 1993; Benya et al., 1995; . The physiological functions regulated by the NMBR in peripheral tissues include the contraction of gastrointestinal and urogenital smooth muscles and pituitary gland secretion (Severi et al., 1991; Rettori et al., 1992; Kilgore et al., 1993; Parkman et al., 1994; Milusheva et al., 1998) .
GRPR (BB2)
The GRPR is a 384-amino acid protein in humans, mice, and rats. The human GRPR shows 51% identity with the human BRS-3 (Fathi et al., 1993) . The chromosomal location for the GRPR gene (named GRPR in humans and Grpr in mice and rats) is localized at chromosome Xp22.2-p22.13 (human), X F4 (mouse), and Xq21 (rat; Table 2 ; Jensen et al., 2012) . Peripheral tissues in which the GRPR is expressed in rodents under physiological conditions include the digestive tract and the developing lung (Spindel et al., 1990; Jensen et al., 2008) . In the brain, autoradiographic studies indicated that the areas containing high densities of GRPRs include the olfactory bulb, the nucleus accumbens, the caudate putamen, the central amygdala, the dorsal hippocampal formation (CA3 area and dentate gyrus), as well as the paraventricular, central medial, and paracentral thalamic nuclei (Wolf et al., 1983; Wolf and Moody, 1985; Zarbin et al., 1985) . The most detailed immunohistochemical characterization of GRPR expression in the mouse brain published so far (Kamichi et al., 2005) showed that GRPR immunore activity was widely distributed in the hippocampal formation, the hypothalamus, the brain stem, cortical areas, the amygdala [particularly in the basolateral (BLA) and central nuclei of the amygdala (CeA)], the NTS and with high densities also observed in the dorsal hippocampus (dHIP).
As with NMBR, GRPR is directly coupled to G q and primarily associated with increased cellular Ca 2+ and activation of the PLC/PKC (Hellmich et al., 1999; Stangelberger et al., 2005) but not the adenylyl cyclase (AC)/cyclic AMP (cAMP)/protein kinase A (PKA) pathway (although there is evidence of increased cAMP levels in response to GRPR activation and functional interactions between GRPR and cAMP/PKA; see, for example, Qin et al., 1995; Chan and Wong, 2005; de Farias et al., 2008) . Cellular responses to GRPR activation also depend on MAPK signaling (Hellmich et al., 1999; Chen and Kroog, 2004; Stangelberger et al., 2005) , and studies in normal tissues or cancer cells have indicated that GRPR signaling interacts with a range of other growth factor receptor systems (e.g., epidermal growth factor receptor, EGFR), signaling enzymes [e.g., tyrosine kinases, phosphatidylinositol 3-kinase (PI3K), and cyclooxygenase-2], and immediateearly genes (e.g., c-fos and c-jun; Szepeshazi et al., 1997; Chatzistamou et al., 2000; Thomas et al., 2005; Hohla et al., 2007; Ishola et al., 2007; Liu et al., 2007; Flores et al., 2008; de Farias et al., 2010; Czepielewski et al., 2012) . The physiological functions of GRPRs in peripheral tissues likely include the regulation of gastrin and somatostatin release from cells in the gastric mucosa, gastric acid secretion, pancreatic secretion, gastrointestinal motility, lung development, and chemoattraction in immune system cells (Ruff et al., 1985; Schubert et al., 1991; Del Rio and De la Fuente, 1994; Niebergall-Roth and Singer, 2001; Ohki-Hamazaki et al., 2005; Jensen et al., 2008; Czepielewski et al., 2012) . Spindel et al., 1990; Wada et al., 1991; Jensen et al. (2012) ; for a review, see Jensen et al., 2008 .
Species

BRS-3 receptor (BB3)
The BRS-3 in humans, rats, and mice has 399 amino acids (Fathi et al., 1993) . The human BRS3 gene is localized at chromosome Xq26-q28, whereas the locations of the mouse and rat Brs3 genes are X A7.1-A7.2 and Xq36, respectively ( Table 2 ; Jensen et al., 2012) . Studies in rats, mice, and monkeys indicate that the BRS-3 is expressed in the testis, the CNS, and the enteric nervous system (Fathi et al., 1993; Ohki-Hamazaki et al., 1997; Sano et al., 2004) , although its physiological role remains unclear and no naturally occurring ligand has been identified . As with NMBR and GRPR, BRS-3 signaling may involve the activation of PLC, PKC, MAPK, and phospholipases (Fathi et al., 1993; Ryan et al., 1998; Weber et al., 2001; Sano et al., 2004) . No involvement of BRS-3 in memory has been demonstrated to date; hence, in the next sections, we will focus on the NMBR and GRPR types of bombesin receptors.
Bombesin receptor regulation of synaptic plasticity and memory
The involvement of bombesin receptors in memory formation has been revealed mostly by studies using sys-temic or intracerebral administration of agonists and antagonists of NMBR and GRPR in rodents submitted to learning tasks. More recently, the use of genetic models, particularly GRPR knockout mice, has allowed the characterization of memory alterations associated with genetic ablation of bombesin receptors. In several of the experiments reviewed below, emotionally motivated memory was examined in rodents using Pavlovian fear conditioning paradigms, whereby an emotionally neutral stimulus (conditioned stimulus, CS), typically a sound (tone or white noise) in ' cued ' fear conditioning or a particular environment (e.g., a chamber or box; context) in ' contextual ' fear conditioning, is presented in conjunction with an innately aversive or unconditioned stimulus (e.g., electric footshock) such that, after repeated pairings, the CS alone acquires the capacity to elicit responses akin to fear. In other experiments, the fear-motivated conditioning model used was inhibitory avoidance, in which animals learn to associate a location in the training apparatus with an aversive stimulus (footshock). Experiments using these models have provided valuable insight into the roles of NMBR and GRPR in emotional memory.
Pharmacological studies
The first experiments directly addressing the effects of BLPs on memory were reported by Flood and Morley (1988) . They showed that systemic or i.c.v. injections of either GRP or bombesin after training could modulate memory retention for a T-maze footshock avoidance task. However, the pattern of effects of GRPR agonists on memory formation was rather complex and dependent on specific experimental conditions. Thus, systemic GRP or bombesin produced memory enhancement when given at lower doses and when the animals were trained with a weak footshock but impaired memory when higher doses or a stronger training protocol were used Morley, 1988, 1989) . This characteristic inverted U-shaped dose-response pattern for the effects of GRPR agonists on memory is not surprising, given that it is often observed for the effects of neuropeptides and other modulatory drugs on memory consolidation (McGaugh, 1989) . When infused i.c.v., both GRP and bombesin enhanced memory. In addition, the memory-enhancing effects of systemic GRP and bombesin were inhibited by vagotomy, indicating that the effects could be at least partially mediated by peripheral stimulation of ascending vagal pathways (Flood and Morley, 1988) . The finding that systemic bombesin given posttraining could enhance memory retention was later confirmed in rats by another laboratory (RashidyPour and Razvani, 1998) . A few years later, Williams and McGaugh (1994) showed that bombesin could enhance memory for inhibitory avoidance and in a radial arm maze when infused directly into the NTS after training.
Studies using systemic injections of selective antagonists indicated that the pharmacological blockade of bombesin receptors could result in memory impairment for emotionally motivated tasks. Thus, pretraining injections of either the NMBR antagonist BIM23127 or the GRPR antagonist [Leu13-(psi-CH 2 NH)-Leu14]BN impaired inhibitory avoidance retention in mice . A series of experiments by Roesler et al. (2004b) showed that the pretraining injection of the selective GRPR antagonist RC-3095 in rats impaired memory for inhibitory avoidance but not for a task with less emotional content, novel object recognition (NOR), indicating that the GRPR is preferentially involved in regulating the formation of emotional, aversively motivated memories, although further studies using low arousing tasks are required to support that conclusion. Similar impairing effects of RC-3095 on inhibitory avoidance memory were obtained with posttraining injections given systemically (Roesler et al., 2004c) , pretraining or posttraining infusions given directly into the dHIP (Roesler et al., 2003; Venturella et al., 2005; Dantas et al., 2006; Preissler et al., 2007) , or posttraining infusions into the BLA (Roesler et al., 2004c) . The effects of systemic or intra-dHIP injections of the GRPR antagonist on inhibitory avoidance memory often followed an inverted U-shaped doseresponse pattern, in which intermediate doses resulted in memory impairment, whereas higher doses had no effect or produced memory enhancement (Roesler et al., 2003 (Roesler et al., , 2004b Dantas et al., 2006) . Conversely, posttraining intradHIP infusion of bombesin resulted in the enhancement of inhibitory avoidance memory at intermediate doses and impairment at higher doses (Roesler et al., 2006b) .
In addition to memory encoding and consolidation, GRPRs might influence the expression, extinction, and reconsolidation of emotional memories. Intra-dHIP infusion of RC-3095 blocked the consolidation of inhibitory avoidance extinction when given after extinction training and produced a transient impairment of reconsolidation-like processes when given after retrieval (Luft et al., 2008) . A series of studies by Merali et al. have examined the effects of pretest administration of bombesin receptor ligands on the expression of fear conditioning. Thus, the central administration of GRP, injected i.c.v. or localized at specific amygdaloid (CeA and BLA) or cortical sites, attenuated the expression of learned fear (as seen by reduced levels of freezing) in response to contextual cues (i.e., in the context in which animals had previously been exposed to shock) and to a tone that had previously been paired with a shock (Mountney et al., 2006 (Mountney et al., , 2008 Merali et al., 2011) . Conversely, the i.c.v. administration of RC-3095 increased freezing . The localized intracerebral microinjection of the GRPR antagonists, however, elicited a more complicated pattern of behavior al responses. Specifically, the administration of the GRPR antagonist, BW2258U89, into the infralimbic cortex (IL) attenuated the freezing response, whereas, at the CeA, the effects were biphasic: the high dose reducing freezing and the low dose increasing freezing (Mountney et al., 2006) . The administration of RC-3095 to the BLA significantly reduced the freezing response to contextual cues but not to the conditioned tone (Mountney et al., 2008) . At first blush, it would appear difficult to reconcile why, under certain conditions, the effects of GRPR antagonists were similar to those of GRP itself. However, it is noteworthy that some GRPR antagonists have intrinsic agonistic activity (De Castiglione and Gozzini, 1996) , which may become evident at certain doses, in a site-specific manner. Furthermore, as noted above, and similar to other peptides, bombesin and GRP and GRPR antagonists have been shown to have an inverted U-shaped dose-response curve wherein low versus higher doses exhibit opposing effects on behavior (Flood and Morley, 1988; Dantas et al., 2006; Roesler et al., 2006b ). Such differential effects may translate into modulation of distinct neuronal circuits and behavioral outcomes.
Although a role for the GRPR in learned fear has been fairly well established, much less is known about the role of NMBRs in fear-related processes. Unlike GRPR, which appears to be more selectively involved in emotionally based learning and memory, NMBRs may play a more generalized role in both innate (unconditioned) anxiety and learned fear-type responses. Indeed, the i. (Chaperon et al., 2012) .
The GRPR might be relevant for CNS development, and studies using neonatal treatments with a GRPR antagonist have been performed in order to examine the long-lasting consequences of GRPR blockade during development. In studies performed by Schr ö der et al., rats given systemic injections of RC-3095 twice daily from postnatal days (PND) 1 -10 showed, among other behavioral alterations, impaired long-term but not short-term memory for both inhibitory avoidance and NOR when trained and tested in the adulthood (Presti-Torres et al., 2007 and also impaired maternal odor preference when tested as infants (Garcia et al., 2010) . The behavioral impairments induced by neonatal GRPR blockade were accompanied by decreases in the mRNA expression of GRPR, the N-methyl-D-aspartate (NMDA) receptor subunit NR1, and EGFR in the cortex and increases in all three receptor mRNAs in the hippocampus. These findings suggest that the disruption of GRPR signaling during the neonatal period can lead to long-lasting memory dysfunction, supporting a role for the GRPR in brain development and memory processes.
Genetic studies
Mice knockout for NMBR (Ohki-Hamazaki et al., 1999) and GRPR have been generated and characterized. One study directly addressing memory in female mice knockout for the NMBR showed that they had impaired inhibitory avoidance memory when the rats were previously exposed to restraint stress, whereas nonstressed mice had normal memory .
In a study using GRPR knockout mice, Shumyatsky et al. (2002) showed that contextual and cued fear conditioning was enhanced by the genetic deletion of GRPR. Consistent with the view that the GRPR is particularly involved in memory for emotionally motivated tasks, memory for a different type of task not involving explicit fear motivation (spatial memory assessed in the Morris water maze) was unaffected in mice lacking GRPR. Importantly, synaptic plasticity measured by long-term potentiation (LTP) in amygdala preparations was enhanced in GRPR knockout mice as well as by a GRPR antagonist in the amygdala from wild-type animals. GRPR was preferentially expressed in amygdalar inhibitory interneurons releasing γ -aminobutyric acid (GABA). The authors proposed that GRP might be released as a cotransmitter from glutamatergic neurons to activate preferentially GRPRs located on GABAergic interneurons. In this model, GRPR signaling would act to stimulate inhibitory transmission within the amygdala and represent an inhibitory constraint for the formation of fear-motivated memories.
Two recent studies further characterized emotional memory and synaptic plasticity in GRPR knockout mice. Martel et al. (2012) found impaired extinction of cued but not contextual fear accompanied by increased c-fos activity in the BLA and reduced c-fos in the prefrontal cortex. Chaperon et al. (2012) found enhanced cued fear conditioning, but unaltered contextual fear conditioning, multipletrial cued fear conditioning, cued fear extinction, and conditioned taste aversion, in GRPR knockout mice. These findings, together with the lack of effect of intra-BLA GRP on fear conditioning expression (see above) and of either GRP or a GRPR antagonist on amygdalar LTP, led the authors to propose that GRPR signaling might play a limited role in regulating fear-motivated memory.
The findings that mice lacking GRPR show enhanced fear conditioning and amygdalar LTP suggest that the GRPR plays an inhibitory role in fear memory formation and seem to contrast the conclusions from several pharmacological studies indicating that GRPR activation usually enhances, whereas its inhibition impairs, memory for fear-motivated tasks. However, as discussed above, the effects of GRPR ligands on memory are rather complex and usually show an inverted U-shaped dose-response pattern in which different drug doses display contrasting effects. It is possible that GRPRs in different brain areas can either stimulate or impair memory depending on the degree of pharmacological activation or inhibition through mechanisms yet to be characterized. Moreover, first-generation knockout mouse models have their own limitations in studies on memory. For example, the use of knockout mice does not allow the investigation of the role of the targeted gene in separate phases of memory (encoding, consolidation, and expression). In addition, it is possible that knockout mice have upregulation of compensatory pathways in response to the gene ablation, and behavioral alterations observed in knockout mice might be caused by abnormal CNS development rather than specific memory processes. These limitations may confound the interpretation of the findings on behavioral phenotypes of knockout mice. Table 3 summarizes the findings from studies examining the effects of pharmacological and genetic manipulation of bombesin receptors.
Brain systems mediating bombesin receptor regulation of memory
As seen above, the pharmacological manipulation of GRPRs specifically in discrete brain areas showing high GRPR expression, namely, the BLA, the dHIP, and the NTS, after training can modulate memory formation. Consistent with a crucial role of the BLA and NTS in mediating the effects of GRPR ligands on emotional memory consolidation, the memory-enhancing effect of posttraining systemic administration of bombesin was attenuated by unilateral lidocaine inactivation of either the amygdala or the NTS (Rashidy-Pour and Razvani, 1998) , and the memory-impairing effect of systemic RC-3095 was blocked by muscimol inactivation of the BLA (Roesler et al., 2006b) . Importantly, Mountney et al. (2011) have recently shown that the levels of GRP measured with in vivo microdialysis are increased in the BLA after fear conditioning, and GRP release correlates with freezing levels. Extensive evidence indicates that the BLA is critical for enabling the modulatory actions of a variety of drugs and hormones on memory consolidation as well as to regulate synaptic plasticity processes involved in memory formation in other brain areas, including the hippocampus (McGaugh, 2002 (McGaugh, , 2004 . The dHIP is a site for LTP and activation of a range of neurochemical cascades, protein synthesis, and gene expression mediating memory consolidation for inhibitory avoidance (Izquierdo and Medina, 1997) . Thus, the expression levels of the GRPR in the BLA and dHIP, as well as the effects of intra-BLA and intra-dHIP infusions of GRPR ligands, and the requirement of the BLA in enabling memory modulation by drugs acting on the GRPR, are strongly consistent with the view that the GRPR acts as a relevant molecular regulator of emotional memory formation. In addition, the fear conditioning studies reviewed above indicate that bombesin receptors in several brain areas, including the PrL, IL, CeA, and BLA, might also modulate the expression of fear-motivated memories (Mountney et al., 2006 (Mountney et al., , 2008 .
Signaling mechanisms mediating bombesin receptor regulation of memory
Experiments using combined or sequential infusions of memory-enhancing doses of bombesin and inhibitors or activators of different intracellular signaling pathways into the dHIP were the first used to investigate the molecular mechanisms mediating the memory modulatory activities of bombesin receptors. The enhancement of inhibitory avoidance memory produced by posttraining intra-dHIP bombesin was prevented by RC-3095 but not by BIM23127, indicating that it depends on GRPR but not NMBR activation. Bombesin-induced memory enhancement was also prevented by inhibitors of PKC, MAPK, PKA, and PI3K (Roesler et al., 2006b (Roesler et al., , 2009 . Conversely, memory enhancement by bombesin was potentiated by the coinfusion of different activators of the dopamine D1/ D5 receptor (D1R) pathway, namely, the D1R agonist SKF 38393, the AC activator forskolin, and the cAMP analog 8-Br-cAMP (Roesler et al., 2006b ). The same stimulators of cAMP/PKA signaling block the memory-impairing effect of GRPR blockade by RC-3095 in the dHIP. These findings indicate that the PKC, MAPK, PI3K, and PKA pathways are critical in mediating memory modulation by hippocampal GRPRs and that GRPR activation can interact with cAMP/PKA signaling in enhancing memory formation in the hippocampus. Because GRPR signaling through G q is not directly coupled with the AC/cAMP/PKA pathway, Roesler et al. (2006b) have hypothesized that increases in Ca 2+ associated with GRPR activation might activate Ca 2+ -responsive hippocampal AC (Wong et al., 1999; Chan and Wong, 2005) , leading to PKA activation. Figure 3 illustrates a model of intracellular signaling associated with GRPR modulation of memory formation in the hippocampus.
Bombesin receptor interactions with other neurotransmitter, hormone, and growth factor systems in regulating memory
The GRP/GRPR system in the brain may interact with signaling triggered by other neurotransmitters, hormones, and neuronal receptors involved in regulating memory consolidation. The enhancement of inhibitory avoidance retention produced by posttraining intra-dHIP infusion of a high dose of RC-3095 was prevented by an otherwise ineffective dose of the GABA A receptor agonist muscimol, suggesting that the memory-enhancing effect of high doses of GRPR antagonists might be mediated by inhibition of hippocampal GABAergic transmission (Dantas et al., 2006) . The memory-impairing effect of a lower dose of intra-dHIP was prevented by a coinfusion of an otherwise infective dose of basic fibroblast growth factor/ fibroblast growth factor-2 as well as by a systemic injection of the glucocorticoid receptor agonist dexamethasone (Venturella et al., 2005) .
Therapeutic implications of bombesin receptors in memory and anxiety disorders
As reviewed above, bombesin receptors in the mammalian brain are likely activated by endogenous BLPs released from neurons as cotransmitters. Moreover, bombesin receptors are highly expressed in brain areas involved in memory formation and expression and regulating emotional responses, and a range of pharmacological and genetic studies in rodents indicates that both NMBR and GRPR can act as molecular regulators of memories associated with emotional arousal. In addition, the presence of BLPs in brain regions known to be activated by stressors, together with findings that exposure to stressors alters the release of BLPs, suggests that bombesin receptors may play a more general role in mediating and integrating stress responses (Merali et al., 2002) . This evidence is consistent with a possible role of deregulated bombesin receptor signaling in memory dysfunction and anxiety disorders. In fact, some human studies suggest that alterations in bombesin receptor function are associated with neurological and psychiatric disorders affecting memory and emotional responses. Thus, bombesin receptor density and bombesin-induced Bombesin (BB)-induced enhancement of emotional memory in the rat dHIP requires PKC, MAPK, PKA, and PI3K and is potentiated by the activation of the D1R/cAMP/PKA pathway (Roesler et al., 2006a (Roesler et al., , 2009 . Bombesin or GRP can activate G q protein (G q )-coupled GRPRs at the postsynaptic membrane, leading to an increase in Ca 2+ and stimulation of the PLC/PKC and ERK/MAPK pathways. D1R is coupled to G s protein (G s ) and AC activation. The D1R-induced cAMP signal might be potentiated by Ca 2+ -induced stimulation of Ca 2+ -responsive types of AC (Wong et al., 1999; Chan and Wong, 2005) , providing a possible mechanism for the requirement of cAMP/PKA signaling for GRPR influences on memory. Modified from Roesler et al. (2006b) .
calcium signaling are altered in fibroblasts from patients with Alzheimer ' s disease (AD; Ito et al., 1994) . In fibroblasts from patients with familial AD presenting the Swedish APP670/671 mutation, elevations in calcium induced by bombesin were reduced by 40% (Gibson et al., 1997) . In addition, GRPR has emerged as a candidate gene in autism spectrum disorders (ASD). A translocation breakpoint on the X chromosome in the first intron of the GRPR gene was described in a patient with autism accompanied by mental retardation and epilepsy (IshikawaBrush et al., 1997) . A subsequent study investigating two polymorphic sites in the second exon of the GRPR gene in patients with autism did not support that the GRPR is a candidate locus for autism (Marui et al., 2004) . However, a possible role of C6S and L181F mutations of the GRPR gene in GRPR function and ASD has been identified in two patients (Seidita et al., 2008) . Evidence from preclinical experiments showing impaired social behavior in rats given neonatal GRPR blockade supports a role for GRPR in ASD (Presti-Torres et al., 2007 . Merali et al. (2006b) described discrete alterations in the levels of NMB and GRP analyzed postmortem in some areas relevant for stress responses in the brains of suicide cases compared to control subjects. Subsequently, an association and linkage analysis of GRP and GRPR as candidate genes in panic disorders did not find a relevant linkage (Hodges et al., 2009) . Further studies are required to establish what, if any, is the significance of alterations in the GRPR gene or receptor-triggered signaling for the pathogenesis of brain disorders. Taking together the evidence from preclinical and human studies, we have proposed (Roesler et al., 2004a (Roesler et al., , 2006a Merali et al., 2006a; Presti-Torres et al., 2007) that bombesin receptors should be investigated as novel therapeutic targets in neurological and psychiatric disorders, particularly those affecting memory and anxiety. Recent preclinical experiments have indicated that, as with central administration, systemically administered GRP is effective at reducing both the expression and the reconsolidation of learned fear, supporting the view that GRP has the potential of alleviating fear memories. The possible relative selectivity of neuronal GRPRs in regulating primarily emotionally influenced aspects of memory might make GRPR signaling a particularly promising target among neuropeptide systems. Human studies examining the effects of GRP administration on satiety and eating behavior (Gutzwiller et al., 1994) and the effects of RC-3095 in patients with cancer have provided preliminary evidence indicating that neither GRP nor a GRPR antagonist induce overt side effects when given intravenously in human subjects, suggesting that the potential therapeutic effect of GRPR ligands could be investigated in patients with CNS disorders involving memory dysfunction and anxiety.
